FABP4 and myeloid sarcoma: Similarly, serum FABP4 levels were increased in patients with diabetes (non-DM: 25.20 ± 1.26 ng/mL; DM: 36.39 ± 1.82 ng/mL, P < 0.001), obesity (non-OB: 25.51 ± 1.40 ng/mL; OB: 41.24 ± 2.32 ng/mL, P < 0.01) and metabolic syndrome (non-MS: 20.39 ± 1.09 ng/mL; MS: 35.90 ± 1.59 ng/mL, P < 0.001) (Figure 1B).